首页> 美国卫生研究院文献>Indian Journal of Clinical Biochemistry >Increased serum concentrations of Soluble CD40 Ligand as a prognostic marker in patients with Acute Coronary Syndrome
【2h】

Increased serum concentrations of Soluble CD40 Ligand as a prognostic marker in patients with Acute Coronary Syndrome

机译:急性冠状动脉综合征患者血清可溶性CD40配体浓度升高作为预后标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

CD40-CD40L interaction plays a significant role in the pathogenesis of atherosclerosis and coronary artery disease. The clinical predictive value of Soluble CD40 Ligand (sCD40L) was evaluated in patients with Acute Coronary Syndrome (ACS) and Non-Cardiac Chest Pain (NCCP). The levels of serum soluble CD 40 ligand were measured by ELISA in 485 patients admitted to emergency care unit, of which 89 patients were diagnosed as NCCP. The levels of sCD40L were significantly increased in patients with ACS when compared to controls and NCCP. Receiver Operator Characteristic (ROC) Curve analysis showed sCD40L to be a good discriminator between patients with ischemic heart disease and patients without ischemic heart disease. The area under the curve was found to be 0.940 with 95% CI (0.915 to 0.960) (P<0.0001). The cut off value from the ROC curve was 2.99 ng/ml, above which sCD40L was considered to be positive. Combined assessment of sCD40L, Troponin I and CK-MB enhanced the risk prediction and early classification of patients. sCD40L seems to be a promising biomarker for identification and risk stratification for patients with acute coronary syndrome.
机译:CD40-CD40L相互作用在动脉粥样硬化和冠状动脉疾病的发病机理中起重要作用。在患有急性冠脉综合征(ACS)和非心脏性胸痛(NCCP)的患者中评估了可溶性CD40配体(sCD40L)的临床预测价值。 ELISA法测定了485名急诊科患者的血清可溶性CD 40配体水平,其中89例被诊断为NCCP。与对照组和NCCP相比,ACS患者的sCD40L水平显着升高。接收者操作员特征(ROC)曲线分析表明,sCD40L是缺血性心脏病患者和非缺血性心脏病患者的良好区分者。发现曲线下的面积为0.940,具有95%CI(0.915至0.960)(P <0.0001)。 ROC曲线的截止值为2.99 ng / ml,高于此值sCD40L被认为是阳性。 sCD40L,肌钙蛋白I和CK-MB的联合评估增强了患者的风险预测和早期分类。 sCD40L似乎是用于急性冠脉综合征患者识别和危险分层的有前途的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号